about
Defects in death-inducing signalling complex formation prevent JNK activation and Fas-mediated apoptosis in DU 145 prostate carcinoma cellsHeat shock proteins--modulators of apoptosis in tumour cellsBetween-group analysis of microarray data.Carbonylation of glycolytic proteins is a key response to drug-induced oxidative stress and apoptosis.Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli.Molecular signals in anti-apoptotic survival pathways.Signalling apoptosis: a radical approach.Targeting inflammatory diseases via apoptotic mechanisms.Live and let die: regulatory mechanisms in Fas-mediated apoptosis.Control of mitochondrial integrity by Bcl-2 family members and caspase-independent cell death.Progesterone Attenuates Microglial-Driven Retinal Degeneration and Stimulates Protective Fractalkine-CX3CR1 Signaling.Apoptosis: a potential therapeutic target for retinal degenerations.Direct oxidative modifications of signalling proteins in mammalian cells and their effects on apoptosis.Retinal ganglion cells: dying to survive.The synthetic progestin norgestrel acts to increase LIF levels in the rd10 mouse model of retinitis pigmentosa.The synthetic progestin norgestrel modulates Nrf2 signaling and acts as an antioxidant in a model of retinal degeneration.Hydrogen peroxide as a cell-survival signaling molecule.Deregulation of cell death (apoptosis): implications for tumor development.Fractalkine-CX3CR1 signaling is critical for progesterone-mediated neuroprotection in the retina.Less stress, more success? Oncological implications of surgery-induced oxidative stress.Preventing retinal apoptosis--is there a common therapeutic theme?Recent advances in reactive oxygen species measurement in biological systems.ROS signalling, NADPH oxidases and cancer.Anisomycin activates JNK and sensitises DU 145 prostate carcinoma cells to Fas mediated apoptosis.BCR-ABL: an anti-apoptosis gene in chronic myelogenous leukemia.The production of a reactive oxygen intermediate during the induction of apoptosis by cytotoxic insult.The repression of apoptosis by activated abl oncogenes in chronic myelogenous leukaemia.Inhibition of protein-tyrosine phosphatase 1B (PTP1B) mediates ubiquitination and degradation of Bcr-Abl protein.New Insight into the Role of Reactive Oxygen Species (ROS) in Cellular Signal-Transduction Processes.Pro-survival redox signalling in progesterone-mediated retinal neuroprotection.Effects of surgery on the cancer stem cell niche.Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.Subcellular localization of the FLT3-ITD oncogene plays a significant role in the production of NOX- and p22phox-derived reactive oxygen species in acute myeloid leukemia.The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF).The synthetic progesterone Norgestrel is neuroprotective in stressed photoreceptor-like cells and retinal explants, mediating its effects via basic fibroblast growth factor, protein kinase A and glycogen synthase kinase 3β signalling.NOX-driven ROS formation in cell transformation of FLT3-ITD-positive AML.7-formyl-10-methylisoellipticine, a novel ellipticine derivative, induces mitochondrial reactive oxygen species (ROS) and shows anti-leukaemic activity in mice.Progesterone receptor signalling in retinal photoreceptor neuroprotection.NADPH oxidase-generated hydrogen peroxide induces DNA damage in mutant FLT3-expressing leukemia cells.Ellipticine derivative induces potent cytostatic effect in acute myeloid leukaemia cells.
P50
Q24299590-6AFE9AF3-CF37-4EC8-A5DE-76D1797F06A5Q28679029-8D5CCAD0-58E7-4C6B-ACCC-0B217209B350Q30756692-F01F2A2E-F6EF-410B-8EC5-765C643CAE58Q33195237-C697A528-BC12-494B-9FED-5A13E7678A36Q34094129-D9B9E3C4-EE26-45C0-B928-C3ABAF78342EQ34177539-01A43EAF-767D-4F51-9EE0-73075ADA1AFBQ34307275-A3B49BB5-FDB1-4ACA-A1B2-6C5BB11931AEQ35193658-61CDF339-944F-4EE5-9045-B27D204C8670Q35538226-ECE22C38-D17D-43E7-B41E-9541CCB05A4EQ35680512-84D4C648-F325-41AA-8586-1824EC750242Q36182897-60824419-BCC9-407F-9A0D-532C2D0F7EF1Q36266079-2B02C598-1982-447F-B901-A99FC75D6DADQ36341949-FDEADEBD-F09A-48E4-84ED-7329ECBFAB73Q36628306-4E7CDDF4-0282-4774-8F61-829D3DA246B5Q36742077-A33EADE4-F3B7-4CCB-AC0C-524B80CA3F74Q37341998-D42EE8BD-4DB2-4C4A-A92F-3D6498A94C72Q37532463-33D4707A-1FCA-46B2-BF08-4A7CFCFA3347Q37605266-C890B27B-B470-4750-8376-C5B082681FDAQ37652175-407A23D9-39C8-4EEA-9C7F-1F93967C985DQ37965449-BA2260FC-38F9-4E15-886F-5AF6686754CCQ37988285-F6576618-492A-4D75-95E9-CC699B7246BAQ38152076-D9041AE0-3139-4691-AE87-E7C1CAB2FAA5Q38238631-64B1F7BB-C05B-4667-A0BF-1C1E7BC05F7AQ38290909-3F5227F7-A5BE-4BEF-925F-B6010D483927Q38293670-8C324FBA-22B4-4B8E-A746-56C83A41A8D2Q38340274-6C788D33-BAF7-457E-AF58-B030A5251FE7Q38357371-DBDBC398-201D-445F-A17E-7E1C869E58EFQ38420727-EA84158E-249D-42C8-82F1-7B5A8D1F748FQ38592588-CC46804D-CD02-4376-89D8-99E97212FDFDQ38703924-19962498-3321-412C-9819-B1BA803B591DQ38711572-3A869C8A-F14D-4CB0-8BC9-7782F1E27308Q38718484-696CDA6C-CB28-40BD-AB0B-A4A22755AA48Q38729843-17BD6AFD-938E-47E7-BE30-7EAB60E103CFQ38795149-F38BAB8E-CBE7-4B60-8224-D55B267F91AEQ38805145-58A534C1-62EE-4EE9-BE78-15F4895E586CQ38808500-97DD8D55-3CBD-42C7-9EBC-ED2C819728CDQ38820155-D039C273-6E76-4475-B4E4-C64336074B1EQ38829565-7094DA5C-A1DE-404A-8E72-D25D2607C12FQ38908003-7BD171EA-EEA2-45CE-A9B7-6762416C5C54Q38967701-E771C73C-2356-495B-B213-93747669D92B
P50
description
researcher ORCID ID = 0000-0003-4626-5613
@en
name
Thomas G Cotter
@ast
Thomas G Cotter
@en
Thomas G Cotter
@nl
type
label
Thomas G Cotter
@ast
Thomas G Cotter
@en
Thomas G Cotter
@nl
prefLabel
Thomas G Cotter
@ast
Thomas G Cotter
@en
Thomas G Cotter
@nl
P1006
P214
P1006
P214
P31
P496
0000-0003-4626-5613
P734
P735
P7859
lccn-no2002014103